1
|
Luker AJ, Graham LJ, Smith TM, Camarena C, Zellner MP, Gilmer JJS, Damle SR, Conrad DH, Bear HD, Martin RK. The DNA methyltransferase inhibitor, guadecitabine, targets tumor-induced myelopoiesis and recovers T cell activity to slow tumor growth in combination with adoptive immunotherapy in a mouse model of breast cancer. BMC Immunol 2020; 21:8. [PMID: 32106810 PMCID: PMC7045411 DOI: 10.1186/s12865-020-0337-5] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2019] [Accepted: 02/14/2020] [Indexed: 12/14/2022] Open
Abstract
Background Myeloid derived suppressor cells (MDSCs) present a significant obstacle to cancer immunotherapy because they dampen anti-tumor cytotoxic T cell responses. Previous groups, including our own, have reported on the myelo-depletive effects of certain chemotherapy agents. We have shown previously that decitabine increased tumor cell Class I and tumor antigen expression, increased ability of tumor cells to stimulate T lymphocytes, depleted tumor-induced MDSC in vivo and augmented immunotherapy of a murine mammary carcinoma. Results In this study, we expand upon this observation by testing a next-generation DNA methyltransferase inhibitor (DNMTi), guadecitabine, which has increased stability in the circulation. Using the 4 T1 murine mammary carcinoma model, in BALB/cJ female mice, we found that guadecitabine significantly reduces tumor burden in a T cell-dependent manner by preventing excessive myeloid proliferation and systemic accumulation of MDSC. The remaining MDSC were shifted to an antigen-presenting phenotype. Building upon our previous publication, we show that guadecitabine enhances the therapeutic effect of adoptively transferred antigen-experienced lymphocytes to diminish tumor growth and improve overall survival. We also show guadecitabine’s versatility with similar tumor reduction and augmentation of immunotherapy in the C57BL/6 J E0771 murine breast cancer model. Conclusions Guadecitabine depleted and altered MDSC, inhibited growth of two different murine mammary carcinomas in vivo, and augmented immunotherapeutic efficacy. Based on these findings, we believe the immune-modulatory effects of guadecitabine can help rescue anti-tumor immune response and contribute to the overall effectiveness of current cancer immunotherapies.
Collapse
Affiliation(s)
- Andrea J Luker
- Department of Microbiology and Immunology, School of Medicine, VCU, Box 980678, Richmond, VA, 23298, USA.,Massey Cancer Center, VCU, Box 980678, Richmond, VA, 23298, USA
| | - Laura J Graham
- Department of Microbiology and Immunology, School of Medicine, VCU, Box 980678, Richmond, VA, 23298, USA.,Massey Cancer Center, VCU, Box 980678, Richmond, VA, 23298, USA
| | - Timothy M Smith
- Department of Microbiology and Immunology, School of Medicine, VCU, Box 980678, Richmond, VA, 23298, USA.,Massey Cancer Center, VCU, Box 980678, Richmond, VA, 23298, USA
| | - Carmen Camarena
- Department of Microbiology and Immunology, School of Medicine, VCU, Box 980678, Richmond, VA, 23298, USA
| | - Matt P Zellner
- Department of Microbiology and Immunology, School of Medicine, VCU, Box 980678, Richmond, VA, 23298, USA
| | - Jamie-Jean S Gilmer
- Department of Biology, College of Humanities and Sciences, VCU, Richmond, VA, USA
| | - Sheela R Damle
- Department of Microbiology and Immunology, School of Medicine, VCU, Box 980678, Richmond, VA, 23298, USA.,Massey Cancer Center, VCU, Box 980678, Richmond, VA, 23298, USA
| | - Daniel H Conrad
- Department of Microbiology and Immunology, School of Medicine, VCU, Box 980678, Richmond, VA, 23298, USA.,Massey Cancer Center, VCU, Box 980678, Richmond, VA, 23298, USA
| | - Harry D Bear
- Department of Microbiology and Immunology, School of Medicine, VCU, Box 980678, Richmond, VA, 23298, USA.,Massey Cancer Center, VCU, Box 980678, Richmond, VA, 23298, USA.,Division of Surgical Oncology, Department of Surgery, VCU, Richmond, VA, USA
| | - Rebecca K Martin
- Department of Microbiology and Immunology, School of Medicine, VCU, Box 980678, Richmond, VA, 23298, USA. .,Massey Cancer Center, VCU, Box 980678, Richmond, VA, 23298, USA.
| |
Collapse
|